ArticleEmerging microbes & infections2024
OXA-48-like carbapenemases in
Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Clinical-Microbiological Discordance and Delayed Mortality in OXA-48/ESBL-Producing Proteus mirabilis Infections.Infectious diseases and therapy · 2026Article
- Genomic insights into one carbapenem-resistant and multidrug-resistantMicrobiology spectrum · 2026Article
- Detection of OXA-23 and OXA-58 inMicrobiology spectrum · 2026Article
- Insights into novel diagnostic assay development, antimicrobial resistance, and pathogenicity inApplied and environmental microbiology · 2026Article
- ConfrontingInfection and drug resistance · 2026Review
- Genomic epidemiology of antimicrobial resistance in Proteus mirabilis: core genome and plasmid-mediated drivers.BMC microbiology · 2025Article
- Review
- Prevalence and characterization of carbapenem-resistant gram-negative bacteria from poultry in Tamil Nadu, India.One health (Amsterdam, Netherlands) · 2025Article
- Outbreak Caused by VIM-1- and VIM-4-PositivePathogens (Basel, Switzerland) · 2025Article
- Genomic Insights of Emerging Multidrug-Resistant OXA-48-Producing ST135Antibiotics (Basel, Switzerland) · 2025Article
- Performance of disk diffusion, gradient test, and VITEK 2 for carbapenem susceptibility testing in OXA-48-like carbapenemase-producingJournal of clinical microbiology · 2025Article
- Evolution of β-Lactam Antibiotic Resistance inMicroorganisms · 2025Review
- Genomic epidemiology and antimicrobial resistance ofFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OXA-48-like enzymes represent the most frequently detected carbapenemases in Enterobacterales in Western Europe, North Africa and the Middle East. In contrast to other species, the presence of OXA-48-like in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.